October 28, 2011 - Physician Prescriptions for LifeVest Top 50,000

INVESTOR CONTACT:

A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

PHYSICIAN PRESCRIPTIONS FOR ZOLL LIFEVEST TOP 50,000   

October 28, 2011CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that more than 50,000 patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest® Wearable Defibrillator.

The LifeVest is worn by patients at risk for SCA, providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

“As an investigator in the original WEARIT/BIROAD clinical trial and the primary investigator for the WEARIT II registry, it is rewarding to see so many patients have benefited from this therapy. The LifeVest plays an important role in the continuum of care for patients at high risk from SCA”, stated Arthur J. Moss, M.D., University of Rochester Medical Center. “LifeVest allows physicians to protect patients during their period of highest risk early after an acute cardiac event such as a myocardial infarction or newly diagnosed nonischemic cardiomyopathy, when other therapies are not appropriate due to the patient’s changing condition and the potential for cardiac recovery.”

“The fact that over 50,000 patients have been prescribed the LifeVest by their physicians is a meaningful milestone, made even more rewarding by the fact that it was reached during Sudden Cardiac Arrest Awareness Month. The powerful result of partnering with physicians to protect so many patients from SCA is that all of these patients benefit from the peace of mind provided by the protection and a patient’s life is being saved almost each and every day by a ZOLL LifeVest,” said Richard A. Packer, Chief Executive Officer of ZOLL.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

For more information, go to www.zoll.com or call 1-800-543-3267.

About ZOLL Medical Corporation


ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010 and updated in the Company’s Quarterly Reports on Form 10-Q filed subsequently to the Form 10-K, including the Form 10-Q Quarterly Report filed on August 8, 2011. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements

Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.